Sydnexis

Sydnexis

Phase 3
San Diego, United StatesFounded 2019sydnexis.com

Pediatric progressive myopia (PPM) is the leading cause of vision loss in children, with risks that extend far beyond the need for glasses, which address symptoms but do not treat the underlying disease. Yet treatment options remain limited — especially for younger children. At Sydnexis, we are focusing on a critical gap in care. We aim to advance innovation that can not only help preserve vision in growing eyes but may offer a new path forward for children and their families.

Market Cap
Private
Pipeline
Patents
Publications

Private Company

Funding information not available

About

Pediatric progressive myopia (PPM) is the leading cause of vision loss in children, with risks that extend far beyond the need for glasses, which address symptoms but do not treat the underlying disease. Yet treatment options remain limited — especially for younger children. At Sydnexis, we are focusing on a critical gap in care. We aim to advance innovation that can not only help preserve vision in growing eyes but may offer a new path forward for children and their families.

Small Molecules